Table B.

Multivariate analysis of relapse for MDS, by monosomal karyotype

		Relative Risk	P-value
Main effect:
Normal	237	1.00a	Poverall < 0.001
MK positive	219	2.39 (1.74–3.29)	< 0.001
Other unfavorable	416	1.50 (1.11–2.04)	0.009
Intermediate	606	1.12 (0.84–1.51)	0.44
Favorable	97	1.19 (0.76–1.86)	0.44
Other significant covariates:
Age at transplant by conditioning intensity, years
0–20 MA	132	1.00a	Poverall < 0.001
21–40 MA	210	1.04 (0.66–1.63)	0.88
41–60 MA	512	1.79 (1.20–2.67)	0.004
41–60 RIC/NMA	277	2.66 (1.69–4.18)	< 0.001
61–64 RIC/NMA	158	2.29 (1.40–3.75)	0.001
> 64 RIC/NMA	113	3.21 (1.89–5.43)	< 0.001
Others	173	1.88 (1.17–3.01)	0.008
Karnofsky score
90–100%	1032	1.00a	Poverall = 0.04
< 90%	476	1.27 (1.04–1.54)	0.02
Missing	67	1.28 (0.85–1.92)	0.24
Conditioning regimen classification
TBI + Cy +- others	233	1.00a	Poverall < 0.001
TBI +- others	150	0.84 (0.56–1.27)	0.41
Bu + Cy +- others	506	0.86 (0.64–1.15)	0.30
Bu + Flud +- others	446	1.02 (0.74–1.40)	0.90
Flud + Mel +- others	153	0.37 (0.23–0.59)	< 0.001
Other conditioning regimen	87	1.29 (0.83–2.00)	0.27
Graft type
Bone marrow	439	1.00a
Peripheral blood	1136	0.70 (0.56–0.87)	0.002
ATG/Alemtuzumab for conditioning or GVHD prophylaxis
ATG alone	447	1.00a	Poverall = 0.005
Alemtuzumab alone	54	1.76 (1.15–2.69)	0.009
No ATG or Alemtuzumab	1074	0.89 (0.72–1.09)	0.25
Planned GM or GCSF (12 days)b
No	876	1.00a
Yes	699	0.79 (0.66–0.95)	0.01
Disease status at transplant
Early	642	1.00a
Advanced	933	1.75 (1.44–2.12)	< 0.001
Contrast
Main effect MK positive vs. other unfavorable		1.59 (1.21–2.09)	< 0.001
Main effect MK positive vs. intermediate		2.13 (1.64–2.76)	< 0.001
Main effect MK positive vs. favorable		2.01 (1.32–3.06)	0.001
Main effect other unfavorable vs. intermediate		1.34 (1.06–1.69)	0.01
Main effect other unfavorable vs. favorable		1.26 (0.84–1.90)	0.27
Main effect intermediate vs. favorable		0.94 (0.63–1.41)	0.78
Age 21–40 MA vs. 41–60 MA		0.58 (0.41–0.81)	0.001
Age 21–40 MA vs. 41–60 RIC/NMA		0.39 (0.26–0.58)	< 0.001
Age 21–40 MA vs. 61–64 RIC/NMA		0.45 (0.29–0.70)	< 0.001
Age 21–40 MA vs. > 64 RIC/NMA		0.32 (0.20–0.52)	< 0.001
Age 21–40 MA vs. others		0.55 (0.36–0.84)	0.005
Age 41–60 MA vs. 41–60 RIC/NMA		0.67 (0.51–0.90)	0.007
Age 41–60 MA vs. 61–64 RIC/NMA		0.78 (0.56–1.10)	0.16
Age 41–60 MA vs. > 64 RIC/NMA		0.56 (0.38–0.82)	0.003
Age 41–60 MA vs. others		0.95 (0.69–1.32)	0.77
Age 41–60 RIC/NMA vs. 61–64 RIC/NMA		1.16 (0.83–1.62)	0.37
Age 41–60 RIC/NMA vs. > 64 RIC/NMA		0.83 (0.57–1.20)	0.32
Age 41–60 RIC/NMA vs. others		1.42 (1.00–2.00)	0.05
Age 61–64 RIC/NMA vs. > 64 RIC/NMA		0.71 (0.47–1.08)	0.11
Age 61–64 RIC/NMA vs. others		1.22 (0.82–1.81)	0.33
Age > 64 RIC/NMA vs. others		1.71 (1.12–2.61)	0.01
Karnofsky score < 90% vs. missing		0.99 (0.65–1.51)	0.97
Conditioning TBI +- others vs. Bu + Cy +- others		0.98 (0.67–1.42)	0.91
Conditioning TBI +- others vs. Bu + Flud +- others		0.82 (0.58–1.16)	0.26
Conditioning TBI +- others vs. Flud + Mel +- others		2.28 (1.43–3.63)	< 0.001
Conditioning TBI +- others vs. other		0.65 (0.42–1.01)	0.06
Conditioning Bu + Cy +- others vs. Bu + Flud +- others		0.84 (0.65–1.09)	0.19
Conditioning Bu + Cy +- others vs. Flud + Mel +- others		2.33 (1.49–3.63)	< 0.001
Conditioning Bu + Cy +- others vs. other		0.67 (0.44–1.00)	0.05
Conditioning Bu + Flud +- others vs. Flud+Mel+- others		2.77 (1.85–4.16)	< 0.001
Conditioning Bu + Flud +- others vs. other		0.79 (0.55–1.15)	0.22
Conditioning Flud + Mel +- others vs. other		0.29 (0.17–0.47)	< 0.001
Alemtuzumab alone vs. No ATG or Alemtuzumab		1.98 (1.31–3.01)	0.001

^aReference group

^bGF within 7d: RR=0.82, p<0.001